Amryt Pharmaceuticals Inc.
Doing business as (A Development Stage Company)
- UEI
- WD35CGRUEWS7
- CAGE
- 6XU08
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- amrytpharma.com
- Founded
- 2015
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Alexion Pharmaceuticals Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| APL Sales I LLC | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Cipla USA Inc. | Warren, NJ | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
About the company
Amryt Pharmaceuticals Inc. Division - doing business as (A Development Stage Company) is a foreign-owned, for-profit corporate entity focused on developing and delivering treatments for patients with rare and orphan diseases. According to its website, Amryt Pharma is a commercial stage specialty pharmaceutical company with lead products including AP101 and AP102, potential treatments for Epidermolysis Bullosa and related rare diseases.
Amryt Pharmaceuticals holds several federal contract IDVs for the delivery of specialty pharmaceutical products to the Department of Veterans Affairs (VA). The company has a $1,000,000 single-award blanket purchase agreement (BPA) with the VA National Acquisition Center for Mycapssa, Juxtapid, and Myalept, medications used to treat acromegaly, homozygous familial hypercholesterolemia, and complications of leptin deficiency, respectively. Orders may be placed through March 2024. Amryt also has a multiple-award federal supply schedule contract worth $225,000 with the VA Veterans Health Administration for pharmaceuticals and hematology products valid until September 2027. Additionally, the company was awarded a $607,722.75 single-award BPA by the VA National Acquisition Center in 2021 for Juxtapid and Myalept, facilitated under the Pharmaceuticals and Drugs schedule. While the VA is the sole customer agency, these IDVs aim to streamline procurement of Amryt's specialized drug products to address rare disease treatment needs for the veteran patient population.
Quick answers
Is Amryt Pharmaceuticals Inc. registered in SAM.gov?
Amryt Pharmaceuticals Inc.'s SAM.gov registration expired on July 30, 2024.
Which contract vehicles does Amryt Pharmaceuticals Inc. hold?
Amryt Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
On GovTribe
See Amryt Pharmaceuticals Inc.'s full federal record
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors